Azomyr

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
02-08-2023
产品特点 产品特点 (SPC)
02-08-2023
公众评估报告 公众评估报告 (PAR)
07-07-2015

有效成分:

desloratadine

可用日期:

N.V. Organon

ATC代码:

R06AX27

INN(国际名称):

desloratadine

治疗组:

Antihistamines for systemic use,

治疗领域:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

疗效迹象:

Azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5.1)urticaria (see section 5.1)

產品總結:

Revision: 52

授权状态:

Authorised

授权日期:

2001-01-15

资料单张

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AZOMYR 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
1.
What Azomyr is and what it is used for
2.
What you need to know before you take Azomyr
3.
How to take Azomyr
4.
Possible side effects
5.
How to store Azomyr
6.
Contents of the pack and other information
1.
WHAT AZOMYR IS AND WHAT IT IS USED FOR
WHAT AZOMYR IS
Azomyr contains desloratadine which is an antihistamine.
HOW AZOMYR WORKS
Azomyr is an antiallergy medicine that does not make you drowsy. It
helps control your allergic
reaction and its symptoms.
WHEN AZOMYR SHOULD BE USED
Azomyr relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages
caused by an allergy, for example, hay fever or allergy to dust mites)
in adults and adolescents
12 years of age and older. These symptoms include sneezing, runny or
itchy nose, itchy palate, and
itchy, red or watery eyes.
Azomyr is also used to relieve the symptoms associated with urticaria
(a skin condition caused by an
allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AZOMYR
DO NOT TAKE AZOMYR
-
if you are allergic to desloratadine, or any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before taking Azomyr:
-

                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Azomyr 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect
This medicinal product contains lactose (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets
Light blue, round and embossed film-coated tablets with elongated
letters “S” and “P” on one side and
plain on the other. The diameter of the film-coated tablet is 6.5 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Azomyr is indicated in adults and adolescents aged 12 years and older
for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over) _
The recommended dose of Azomyr is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Azomyr 5 mg film-coated tablets in children
below the age of 12 years have
not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Renal function impairment
In the ca
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 02-08-2023
产品特点 产品特点 保加利亚文 02-08-2023
公众评估报告 公众评估报告 保加利亚文 07-07-2015
资料单张 资料单张 西班牙文 02-08-2023
产品特点 产品特点 西班牙文 02-08-2023
公众评估报告 公众评估报告 西班牙文 07-07-2015
资料单张 资料单张 捷克文 02-08-2023
产品特点 产品特点 捷克文 02-08-2023
公众评估报告 公众评估报告 捷克文 07-07-2015
资料单张 资料单张 丹麦文 02-08-2023
产品特点 产品特点 丹麦文 02-08-2023
公众评估报告 公众评估报告 丹麦文 07-07-2015
资料单张 资料单张 德文 02-08-2023
产品特点 产品特点 德文 02-08-2023
公众评估报告 公众评估报告 德文 07-07-2015
资料单张 资料单张 爱沙尼亚文 02-08-2023
产品特点 产品特点 爱沙尼亚文 02-08-2023
公众评估报告 公众评估报告 爱沙尼亚文 07-07-2015
资料单张 资料单张 希腊文 02-08-2023
产品特点 产品特点 希腊文 02-08-2023
公众评估报告 公众评估报告 希腊文 07-07-2015
资料单张 资料单张 法文 02-08-2023
产品特点 产品特点 法文 02-08-2023
公众评估报告 公众评估报告 法文 07-07-2015
资料单张 资料单张 意大利文 02-08-2023
产品特点 产品特点 意大利文 02-08-2023
公众评估报告 公众评估报告 意大利文 07-07-2015
资料单张 资料单张 拉脱维亚文 02-08-2023
产品特点 产品特点 拉脱维亚文 02-08-2023
公众评估报告 公众评估报告 拉脱维亚文 07-07-2015
资料单张 资料单张 立陶宛文 02-08-2023
产品特点 产品特点 立陶宛文 02-08-2023
公众评估报告 公众评估报告 立陶宛文 07-07-2015
资料单张 资料单张 匈牙利文 02-08-2023
产品特点 产品特点 匈牙利文 02-08-2023
公众评估报告 公众评估报告 匈牙利文 07-07-2015
资料单张 资料单张 马耳他文 02-08-2023
产品特点 产品特点 马耳他文 02-08-2023
公众评估报告 公众评估报告 马耳他文 07-07-2015
资料单张 资料单张 荷兰文 02-08-2023
产品特点 产品特点 荷兰文 02-08-2023
公众评估报告 公众评估报告 荷兰文 07-07-2015
资料单张 资料单张 波兰文 02-08-2023
产品特点 产品特点 波兰文 02-08-2023
公众评估报告 公众评估报告 波兰文 07-07-2015
资料单张 资料单张 葡萄牙文 02-08-2023
产品特点 产品特点 葡萄牙文 02-08-2023
公众评估报告 公众评估报告 葡萄牙文 07-07-2015
资料单张 资料单张 罗马尼亚文 02-08-2023
产品特点 产品特点 罗马尼亚文 02-08-2023
公众评估报告 公众评估报告 罗马尼亚文 07-07-2015
资料单张 资料单张 斯洛伐克文 02-08-2023
产品特点 产品特点 斯洛伐克文 02-08-2023
公众评估报告 公众评估报告 斯洛伐克文 07-07-2015
资料单张 资料单张 斯洛文尼亚文 02-08-2023
产品特点 产品特点 斯洛文尼亚文 02-08-2023
公众评估报告 公众评估报告 斯洛文尼亚文 07-07-2015
资料单张 资料单张 芬兰文 02-08-2023
产品特点 产品特点 芬兰文 02-08-2023
公众评估报告 公众评估报告 芬兰文 07-07-2015
资料单张 资料单张 瑞典文 02-08-2023
产品特点 产品特点 瑞典文 02-08-2023
公众评估报告 公众评估报告 瑞典文 07-07-2015
资料单张 资料单张 挪威文 02-08-2023
产品特点 产品特点 挪威文 02-08-2023
资料单张 资料单张 冰岛文 02-08-2023
产品特点 产品特点 冰岛文 02-08-2023
资料单张 资料单张 克罗地亚文 02-08-2023
产品特点 产品特点 克罗地亚文 02-08-2023
公众评估报告 公众评估报告 克罗地亚文 07-07-2015

搜索与此产品相关的警报

查看文件历史